Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 7297 participants.
Also called NCT05581303
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 7,297 participants
- Sponsor
- Registry
-
NCT05581303 -
2022-501608-85
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, Austria, Brazil, Bulgaria, China, Czechia, Estonia, Finland, France, Germany, Greece, Hong Kong SAR China, Hungary, Iceland, Italy, Japan, Mexico, Norway, Poland, South Korea, Spain, Sweden, Taiwan
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05581303. Randomized; double masking; primary purpose treatment. Start 2022-12-14 (actual); primary completion 2028-03-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
- Condition
- Atherosclerotic Cardiovascular Disease
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Olpasiran
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct05581303- Content hash
a2ac9f8a13b1fd219b9de03f5b184712aa01624cc3bc8a96cea99715cd9b9c07